Contrasting Collegium Pharmaceutical (COLL) & The Competition
Collegium Pharmaceutical (NASDAQ: COLL) is one of 115 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Collegium Pharmaceutical to related companies based on the strength of its risk, analyst recommendations, institutional ownership, valuation, profitability, dividends and earnings.
Institutional & Insider Ownership
83.0% of Collegium Pharmaceutical shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.8% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Collegium Pharmaceutical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Collegium Pharmaceutical Competitors||-2,882.40%||-67.83%||-8.80%|
Risk and Volatility
Collegium Pharmaceutical has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s peers have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Collegium Pharmaceutical and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Collegium Pharmaceutical Competitors||822||3689||6726||182||2.55|
Collegium Pharmaceutical currently has a consensus target price of $20.00, indicating a potential upside of 75.44%. As a group, “Pharmaceuticals” companies have a potential upside of 22.75%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than its peers.
Earnings & Valuation
This table compares Collegium Pharmaceutical and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Collegium Pharmaceutical||$7.44 million||-$97.95 million||-3.11|
|Collegium Pharmaceutical Competitors||$8.08 billion||$2.64 billion||-0.35|
Collegium Pharmaceutical’s peers have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.